| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 147,589 | 300,484 | ||
| Short-term available-for-sale investments | 98,745 | 145,380 | ||
| Accounts receivable, net | 115,268 | 114,367 | ||
| Inventories, net | 157,680 | 148,163 | ||
| Prepaid expenses and other current assets | 43,469 | 37,219 | ||
| Total current assets | 562,751 | 745,613 | ||
| Fixed assets, net | 147,388 | 155,178 | ||
| Right-of-use assets, net | 44,266 | 46,528 | ||
| Goodwill | 20,317 | 20,300 | ||
| Intangible assets, net | 382,396 | 422,563 | ||
| Deferred tax assets | 120,188 | 128,270 | ||
| Investments and other assets | 20,271 | 18,810 | ||
| Total assets | 1,297,577 | 1,537,262 | ||
| Current portion of convertible senior notes, net | - | 202,397 | ||
| Accounts payable | 17,687 | 30,124 | ||
| Accrued expenses | 79,643 | 71,023 | ||
| Lease liabilities | 9,748 | 9,620 | ||
| Current portion of long-term debt, net | 0 | - | ||
| Total current liabilities | 107,078 | 313,164 | ||
| Long-term debt, net | 376,721 | - | ||
| Convertible senior notes, net | - | 280,267 | ||
| Lease liabilities | 38,839 | 41,291 | ||
| Contingent consideration | 17,834 | 17,209 | ||
| Long-term debt, net | - | 97,828 | ||
| Deferred tax liabilities | 4,587 | 4,583 | ||
| Other liabilities | 25,304 | 25,153 | ||
| Total liabilities | 570,363 | 779,495 | ||
| Common stock, par value 0.001 250,000,000 shares authorized 47,735,248 shares issued and 42,965,902 shares outstanding at september30, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at december31, 2024 | 48 | 48 | ||
| Treasury stock, at cost, inclusive of excise tax and broker fees, 4,769,346 and 837,240 shares at september30, 2025 and december31, 2024, respectively | 125,543 | 75,515 | ||
| Additional paid-in capital | 1,049,545 | 1,035,563 | ||
| Accumulated deficit | -200,959 | -206,391 | ||
| Accumulated other comprehensive income | 4,123 | 4,062 | ||
| Total stockholders equity | 727,214 | 757,767 | ||
| Total liabilities and stockholders equity | 1,297,577 | 1,537,262 | ||
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)